KR970003440A - 삼환 5,6-디하이드로-9H-피라졸로[3,4-c]-1,2,4-트리아졸로[4,3-α]피리딘 - Google Patents
삼환 5,6-디하이드로-9H-피라졸로[3,4-c]-1,2,4-트리아졸로[4,3-α]피리딘 Download PDFInfo
- Publication number
- KR970003440A KR970003440A KR1019960020169A KR19960020169A KR970003440A KR 970003440 A KR970003440 A KR 970003440A KR 1019960020169 A KR1019960020169 A KR 1019960020169A KR 19960020169 A KR19960020169 A KR 19960020169A KR 970003440 A KR970003440 A KR 970003440A
- Authority
- KR
- South Korea
- Prior art keywords
- alkyl
- triazolo
- pyrazolo
- dihydro
- pyridine
- Prior art date
Links
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 title claims 20
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 title claims 10
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims abstract 11
- 102000003390 tumor necrosis factor Human genes 0.000 claims abstract 11
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 claims abstract 10
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 claims abstract 10
- 150000001875 compounds Chemical class 0.000 claims abstract 10
- 208000027866 inflammatory disease Diseases 0.000 claims abstract 4
- 208000030507 AIDS Diseases 0.000 claims abstract 3
- 206010006895 Cachexia Diseases 0.000 claims abstract 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims abstract 3
- 206010012434 Dermatitis allergic Diseases 0.000 claims abstract 3
- 201000004681 Psoriasis Diseases 0.000 claims abstract 3
- 206010039085 Rhinitis allergic Diseases 0.000 claims abstract 3
- 206010040047 Sepsis Diseases 0.000 claims abstract 3
- 201000010105 allergic rhinitis Diseases 0.000 claims abstract 3
- 206010003246 arthritis Diseases 0.000 claims abstract 3
- 208000006673 asthma Diseases 0.000 claims abstract 3
- 201000008937 atopic dermatitis Diseases 0.000 claims abstract 3
- 208000010668 atopic eczema Diseases 0.000 claims abstract 3
- 206010006451 bronchitis Diseases 0.000 claims abstract 3
- 150000003839 salts Chemical class 0.000 claims abstract 3
- 201000010099 disease Diseases 0.000 claims abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract 2
- 230000000694 effects Effects 0.000 claims abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 8
- 239000001257 hydrogen Substances 0.000 claims 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 6
- 125000000217 alkyl group Chemical group 0.000 claims 5
- 229910052736 halogen Inorganic materials 0.000 claims 4
- 150000002367 halogens Chemical class 0.000 claims 4
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 3
- 125000006729 (C2-C5) alkenyl group Chemical group 0.000 claims 3
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 3
- 229910005965 SO 2 Inorganic materials 0.000 claims 3
- 125000003342 alkenyl group Chemical group 0.000 claims 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 3
- -1 1 -methylcyclohex-1 -yl Chemical group 0.000 claims 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 239000001301 oxygen Substances 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 239000011593 sulfur Substances 0.000 claims 2
- 125000006526 (C1-C2) alkyl group Chemical group 0.000 claims 1
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
- 125000006833 (C1-C5) alkylene group Chemical group 0.000 claims 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 1
- 125000006701 (C1-C7) alkyl group Chemical group 0.000 claims 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 1
- 125000004399 C1-C4 alkenyl group Chemical group 0.000 claims 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 1
- DHCOPPHTVOXDKU-UHFFFAOYSA-N Tofimilast Chemical compound C1CN2C(C=3SC=CC=3)=NN=C2C2=C1C(CC)=NN2C1CCCC1 DHCOPPHTVOXDKU-UHFFFAOYSA-N 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 1
- 230000003110 anti-inflammatory effect Effects 0.000 claims 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 claims 1
- 125000000000 cycloalkoxy group Chemical group 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
본 발명은 하기 일반식(Ⅰ)의 화합물에 관한 것이다:
상기 식에서, R1, R2, R3, R9및 R10은 상기 정의한 바와 같다. 일반식(Ⅰ)의 화합물 및 그의 약학적으로 허용가능한 염은 포스포디에스테라제(PDE) Ⅳ형 및 종양 괴사 인자(TNF) 생성을 저해하고, 포스포디에스테라제(PDE) Ⅳ형 활성을 특징으로 하는 천식, 관절염, 기관지염, 만성 폐색성 기도 질환, 건선, 알레르기성 비염, 피부염 및 기타 염증성 질환 뿐만 아니라 TNF의 생성에 관련된 AIDS, 패혈증, 패혈성, 쇽크 및 악액질과 같은 기타 질환을 치료하는데 유용하다.
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (8)
- 하기 일반식(Ⅰ)의 화합물 및 그의 약학적으로 허용가능한 염:상기 식에서, R1은 수소, (C1- C6)알킬, (C2- C4)알케닐, 페닐, 디메틸아미노, (C3- C6)사이클로알킬, (C3- C6)사이클로알킬(C1- C3)알킬 또는 (C1- C6)아실이고, 여기서 상기 알킬, 페닐 또는 알케닐 그룹은 2개 이하의 하이드록시, (C1- C3)알킬 또는 트리플루오로메틸 그룹, 또는 3개 이하의 할로겐으로 치환될 수 있고; R2및 R3는 수소, (C1- C14)알킬, (C1- C7)알콕시(C1- C7)알킬, (C2- C14)알케닐, (C3- C7)사이클로알킬, (C3- C7)사이클로알킬(C1- C2)알킬, 포화 또는 불포화 (C4- C7)헤테로사이클릭(CH2)n그룹(여기서, n은 0, 1 또는 2이고, 헤테로 원자로서 산소, 황, 설포닐, 질소 및 NR4로 구성되는 그룹중 1 또는 2개를 포함한다), 또는 하기 일반식(Ⅱ)의 그룹으로 구성되는 그룹중에서 각각 독립적으로 선택되고:a는 1 내지 5의 정수이고; b 및 c는 0 또는 1이고; R5는 수소, 하이드록시, (C1- C5)알킬, (C2- C5)알케닐, (C1- C5)알콕시, (C3- C6)사이클로알콕시, 할로겐, 트리플루오로메틸, CO2R6, CONR6R7, NR6R7, NO2또는 SO2NR6R7이고; R6및 R7은 각각 독립적으로 수소 또는 (C1- C4)알킬이고; Z는 산소, 황, SO2, CO 또는 NR|8이고; R8은 수소 또는 (C1- C4)알킬이고; Y는 2개 이하의 (C1- C7)알킬 또는 (C3- C7)사이클로알킬 그룹으로 임의로 치환된 (C1- C5)알킬렌 또는 (C2- C5)알케닐이고, 여기서 상기 알킬, 알케닐, 사이클로알킬, 알콕시알킬 또는 헤테로사이클릭 그룹은 각각 (C1- C2)알킬, 트리플루오로메틸 또는 할로겐으로 구성되는 1 내지 14개, 바람직하게는 1 내지 5개의 그룹으로 치환될 수 있고, 그리고 R9및 R10은 수소, (C1- C6)알킬, (C1- C6)알콕시, (C6- C10)아릴 및 (C6- C10)아릴옥시로 구성되는 그룹중에서 각각 독립적으로 선택된다.
- 제1항에 있어서, R1이 메틸, 에틸 또는 이소프로필인 화합물.
- 제1항에 있어서, R3이 (C1- C6)알킬, (C2- C6)알케닐, (C3- C7)사이클로알킬,(C3- C7)사이클로알킬(C1- C2)알킬, 또는 수소, 하이드록시, (C1- C5)알킬, (C2- C5)알케닐, (C1- C5)알콕시, 할로겐, 트리플루오로메틸, CO2R6, CONR6R7, NR6R7, NO2또는 SO2NR6R7로 구성되는 그룹중 1 또는 2개로 임의로 치환된 페닐이고, R6및 R7이 각각 독립적으로 수소 또는 (C1- C4)알킬인 화합물.
- 제1항에 있어서, 9 - 사이클로펜틸 - 5,6 - 디하이드로 - 7 - 에틸 - 3 - 페닐 - 9H - 피라졸로[3,4 - c] - 1,2,4 - 트리아졸로[4,3 - α]피리딘; 9 - 사이클로펜틸 - 5,6 - 디하이드로 - 7 - 에틸 - 3 - (4 - 피리딜) - 9H - 피라졸로[3,4 - c] - 1,2,4 - 트리아졸로[4,3 - α]피리딘; 9 - 사이클로펜틸 - 5,6 - 디하이드로 - 7 - 에틸 - 3 - (3 - 테닐) - 9H - 피라졸로[3,4 - c] - 1,2,4 - 트리아졸로[4,3 - α]피리딘; 3,9 - 디사이클로펜틸 - 5,6 - 디하이드로 - 7 - 에틸 - 9H - 피라졸로[3,4 - c] - 1,2,4 - 트리아졸로[4,3 - α]피리딘; 9 - 사이클로펜틸 - 5,6 - 디하이드로 - 7 - 에틸 - 3 - (1 - 메틸사이클로헥스 - 1 - 일) - 9H - 피라졸로[3,4 - c] - 1,2,4 - 트리아졸로[4,3 - α]피리딘; 3 - (3급 - 부틸) - 9 - 사이클로펜틸 - 5,6 - 디하이드로 - 7 - 에틸 - 9H - 피라졸로[3,4 - c] - 1,2,4 - 트리아졸로[4,3 - α]피리딘; 9 - 사이클로펜틸 - 5,6 - 디하이드로 - 7 - 에틸 - 3 - (티엔 - 2 - 일) 9H - 피라졸로[3,4 - c] - 1,2,4 - 트리아졸로[4,3 - α]피리딘; 3 - (2 - 클로로페닐 - 9 - 사이클로펜틸 - 5,6 - 디하이드로 - 7 - 에틸 - 9H - 피라졸로[3,4 - c] - 1,2,4 - 트리아졸로[4,3 - α]피리딘; 9 - 사이클로펜틸 - 5,6 - 디하이드로 - 7 - 에틸 - 3(2 - 요오드페닐) - 9H - 피라졸로[3,4 - c] - 1,2,4 - 트리아졸로[4,3 - α]피리딘; 및 5,6 - 디하이드로 - 7 - 에틸 - 9 - (4 - 플루오로페닐) - 3 - (1 - 메틸사이클로헥스 - 1 - 일) - 9H - 피라졸로[3,4 - c] - 1,2,4 - 트리아졸로[4,3 - α]피리딘으로 구성되는 그룹으로부터 선택된 화합물.
- 제1항에 따르는 화합물의 효과량을 환자에게 투여하는 것을 포함하는, 포스포디에스테라제(PDE) Ⅳ형 및 종양 괴사 인자(TNF) 생성의 저해 방법.
- 항염증성 양의 일반식(Ⅰ)의 화합물 및 그의 약학적으로 허용가능한 염을 포유동물에게 투여하는 것을 포함하는, 포유동물에 있어서 염증성 질환의 치료 방법.
- 제1항에 따르는 화합물의 효과량을 환자에게 투여하는 것을 포함하는, 천식, 관절염, 기관지염, 만성 폐색성 기도 질환, 건선, 알레르기성 비염, 피부염 및 기타 염증성 질환 뿐만 아니라 AIDS, 패혈증, 패혈성 쇽크 및 종양 괴사 인자(TNF) 생성에 관련된 악액질과 같은 기타 질환으로 구성되는 그룹 중에서 선택된 질환의 치료 또는 예방 방법.
- 제1항에 따르는 효과량의 화합물 및 약학적으로 허용가능한 담체를 포함하는, (a) 포스포디에스테라제(PDE) Ⅳ형 활성을 특징으로 하는 천식, 관절염, 기관지염, 만성 폐색성 기도 질환, 건선, 알레르기성 비염, 피부염 및 기타 염증성 질환, 종양 괴사 인자(TNF) 생성에 관련된 AIDS, 패혈성 쇽크 및 악액질과 같은 기타 질환의 치료, 또는 (b) 포스포디에스테라제 (PDE) Ⅳ형 및 종양 괴사 인자(TNF) 생성의 저해를 위한 약학 조성물.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1019980044720A KR100225719B1 (en) | 1995-06-06 | 1998-10-24 | Pharmaceutical compositions containing tricyclic 5,6-dihydro-9h-pyrazolo[3,4-c]-1,2,4-triazolo-[4,3-alpha]pyridines |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| WOPCT/IB95/00429 | 1995-06-06 | ||
| PCT/IB1995/000429 WO1996039408A1 (en) | 1995-06-06 | 1995-06-06 | TRICYCLIC 5,6-DIHYDRO-9H-PYRAZOLO[3,4-c]-1,2,4-TRIAZOLO[4,3-α]PYRIDINES |
| CA002223624A CA2223624C (en) | 1995-06-06 | 1995-06-06 | Tricyclic 5,6-dihydro-9h-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-.alpha.]pyridines |
| HU9601541A HUP9601541A3 (en) | 1995-06-06 | 1996-06-05 | Tricyclic 5,6-dihydro-9h-pyrazolo[3,4-c]-1,2,4-triazolol[4,3-a]-pyridines and pharmaceutical compositions containing them |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR970003440A true KR970003440A (ko) | 1997-01-28 |
| KR100191972B1 KR100191972B1 (ko) | 1999-06-15 |
Family
ID=89994031
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019960020169A KR100191972B1 (ko) | 1995-06-06 | 1996-06-05 | 삼환5,6-디하이드로-9h-피라졸로[3,4-c]-1,2,4-트리아졸로[4,3-a]피리딘 |
| KR1019980044720A KR100225719B1 (en) | 1995-06-06 | 1998-10-24 | Pharmaceutical compositions containing tricyclic 5,6-dihydro-9h-pyrazolo[3,4-c]-1,2,4-triazolo-[4,3-alpha]pyridines |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019980044720A KR100225719B1 (en) | 1995-06-06 | 1998-10-24 | Pharmaceutical compositions containing tricyclic 5,6-dihydro-9h-pyrazolo[3,4-c]-1,2,4-triazolo-[4,3-alpha]pyridines |
Country Status (43)
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2792938B1 (fr) * | 1999-04-28 | 2001-07-06 | Warner Lambert Co | NOUVELLES 1-AMINO TRIAZOLO [4,3-a] QUINAZOLINE-5-ONES INHIBITRICES DE PHOSPHODIESTERASES IV |
| EP1380585B1 (en) * | 1999-04-30 | 2004-11-10 | Pfizer Products Inc. | Pyrazolopyridinone as intermediate |
| US6326495B2 (en) * | 1999-04-30 | 2001-12-04 | Pfizer Inc. | Process for preparing 8-cyclopentyl-6-ethyl-3-[substituted]-5,8-dihydro-4H-1,2,3a,7,8-pentaaza-as-indacenes and intermediates useful therein |
| JP5038568B2 (ja) | 1999-08-21 | 2012-10-03 | ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング | 協力剤の組合せ物 |
| EP1265861A2 (en) * | 2000-03-16 | 2002-12-18 | Inflazyme Pharmaceuticals, Ltd. | Benzylated pde4 inhibitors |
| EP1395288A1 (en) * | 2001-05-25 | 2004-03-10 | Pfizer Inc. | A pde 4 inhibitor and an anti-cholinergic agent in combination for treating obstructive airways diseases |
| ATE347361T1 (de) * | 2001-05-25 | 2006-12-15 | Boehringer Ingelheim Pharma | Kombination eines pde4-inhibitors mit tiotropium zur behandlung obstruktiver atemwegserkrankungen |
| GB0122031D0 (en) * | 2001-09-12 | 2001-10-31 | Pfizer Ltd | Use of pde4 inhibitors in a dry powder inhaler |
| GB0129395D0 (en) * | 2001-12-07 | 2002-01-30 | Pfizer Ltd | Pharmaceutical combination |
| US20050107420A1 (en) * | 2002-05-23 | 2005-05-19 | Boehringe Ingelheim Pharma Gmbh & Co. Kg | Combination of a PDE4 inhibitor and tiotropium or derivative thereof for treating obstructive airways and other inflammatory diseases |
| WO2006075748A1 (ja) * | 2005-01-17 | 2006-07-20 | Santen Pharmaceutical Co., Ltd. | アレルギー性結膜疾患治療剤 |
| RU2008119323A (ru) | 2005-10-19 | 2009-11-27 | Рэнбакси Лабораториз Лимитед (In) | Фармацевтические композиции мускаринового рецептора |
| EA032476B1 (ru) | 2006-07-05 | 2019-06-28 | Астразенека Аб | ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СПОСОБ ЕЁ ПОЛУЧЕНИЯ И ЛЕКАРСТВЕННОЕ СРЕДСТВО, СОДЕРЖАЩЕЕ ИНГИБИТОРЫ HMG-CoA-РЕДУКТАЗЫ И ФОСФОДИЭСТЕРАЗЫ 4, ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ ВОСПАЛИТЕЛЬНЫХ ЗАБОЛЕВАНИЙ ЛЕГКИХ |
| EP2350084B1 (en) * | 2008-10-17 | 2015-06-24 | Boehringer Ingelheim International GmbH | Tetra-aza-heterocycles as phosphatidylinositol-3-kinases (pi3-kinases) inhibitor |
| EP2507244B1 (en) | 2009-12-04 | 2014-11-05 | Nerviano Medical Sciences S.r.l. | Tricyclopyrazole derivatives |
| WO2013084182A1 (en) | 2011-12-08 | 2013-06-13 | Glenmark Pharmaceuticals S.A. | Pharmaceutical composition that includes a pde4 enzyme inhibitor and an analgesic agent |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3697532A (en) * | 1970-08-12 | 1972-10-10 | Squibb & Sons Inc | 5-methyldipyrazolo {8 3,4-b;3{40 ,4{40 -d{9 {0 pyridin-3(2h)-ones |
| RU2131876C1 (ru) * | 1993-07-06 | 1999-06-20 | Пфайзер Инк. | Бициклические тетрагидропиразолпиридины или их фармацевтически приемлемые соли, фармацевтическая композиция, способ ингибирования фосфодиэстеразы, способ лечения |
| CA2143143A1 (en) * | 1994-03-08 | 1995-09-09 | Toshihiko Tanaka | 3-phenylpyrrolidine derivatives |
-
1995
- 1995-06-06 US US08/973,590 patent/US6004974A/en not_active Expired - Fee Related
- 1995-06-06 MX MX9709897A patent/MX9709897A/es unknown
- 1995-06-06 JP JP08511176A patent/JP3107827B2/ja not_active Expired - Fee Related
- 1995-06-06 SK SK718-96A patent/SK282167B6/sk unknown
- 1995-06-06 DE DE69525978T patent/DE69525978T2/de not_active Expired - Fee Related
- 1995-06-06 CA CA002223624A patent/CA2223624C/en not_active Expired - Fee Related
- 1995-06-06 WO PCT/IB1995/000429 patent/WO1996039408A1/en active IP Right Grant
- 1995-06-06 EP EP95918707A patent/EP0837860B1/en not_active Expired - Lifetime
- 1995-06-06 ES ES95918707T patent/ES2172583T3/es not_active Expired - Lifetime
- 1995-06-06 AT AT95918707T patent/ATE214700T1/de not_active IP Right Cessation
- 1995-06-06 PT PT95918707T patent/PT837860E/pt unknown
- 1995-06-06 DK DK95918707T patent/DK0837860T3/da active
-
1996
- 1996-05-02 TW TW085105271A patent/TW460469B/zh not_active IP Right Cessation
- 1996-05-06 AP APAP/P/1996/000806A patent/AP609A/en active
- 1996-05-20 AR ARP960102626A patent/AR002745A1/es unknown
- 1996-05-27 PL PL96314459A patent/PL184195B1/pl not_active IP Right Cessation
- 1996-05-30 IL IL11848596A patent/IL118485A/xx not_active IP Right Cessation
- 1996-06-03 IS IS4350A patent/IS1913B/is unknown
- 1996-06-04 BR BR9602627A patent/BR9602627A/pt active Search and Examination
- 1996-06-04 LV LVP-96-174A patent/LV11620B/en unknown
- 1996-06-04 SA SA96170065A patent/SA96170065B1/ar unknown
- 1996-06-05 NZ NZ286734A patent/NZ286734A/en unknown
- 1996-06-05 KR KR1019960020169A patent/KR100191972B1/ko not_active IP Right Cessation
- 1996-06-05 AU AU54773/96A patent/AU694871B2/en not_active Ceased
- 1996-06-05 MA MA24263A patent/MA23893A1/fr unknown
- 1996-06-05 CZ CZ19961626A patent/CZ287251B6/cs not_active IP Right Cessation
- 1996-06-05 HU HU9601541A patent/HUP9601541A3/hu unknown
- 1996-06-05 SG SG1996009983A patent/SG54341A1/en unknown
- 1996-06-05 NO NO962320A patent/NO306256B1/no unknown
- 1996-06-05 BG BG100640A patent/BG62568B1/bg unknown
- 1996-06-05 RU RU96111027/04A patent/RU2161158C2/ru not_active IP Right Cessation
- 1996-06-05 YU YU34696A patent/YU49346B/sh unknown
- 1996-06-05 TN TNTNSN96083A patent/TNSN96083A1/fr unknown
- 1996-06-05 MY MYPI96002201A patent/MY116527A/en unknown
- 1996-06-05 DZ DZ960088A patent/DZ2044A1/fr active
- 1996-06-06 RO RO96-01157A patent/RO115881B1/ro unknown
- 1996-06-06 SI SI9600186A patent/SI9600186A/sl not_active IP Right Cessation
- 1996-06-06 HR HR960268A patent/HRP960268B1/xx not_active IP Right Cessation
- 1996-06-06 OA OA60834A patent/OA10458A/en unknown
- 1996-06-06 CN CN96107630A patent/CN1061044C/zh not_active Expired - Fee Related
- 1996-06-06 CO CO96029521A patent/CO4700460A1/es unknown
- 1996-06-06 TR TR96/00482A patent/TR199600482A1/xx unknown
-
1997
- 1997-12-05 FI FI974434A patent/FI114097B/fi active
-
1998
- 1998-10-24 KR KR1019980044720A patent/KR100225719B1/ko not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR970003440A (ko) | 삼환 5,6-디하이드로-9H-피라졸로[3,4-c]-1,2,4-트리아졸로[4,3-α]피리딘 | |
| KR960703852A (ko) | 이환상 테트라하이드로 피라졸로피리딘(bicyclic tetrahydro pyrazolopyridines) | |
| BR112020022224A2 (pt) | inibidores heterocíclicos substituídos de ptpn11 | |
| DE602004008945T2 (de) | Thienopyrrole als antivirale mittel | |
| KR960706494A (ko) | 혈소판 활성화 인자 길항물질 : 이미다조피리딘 인돌(Platelet activating factor antagonists : lmidazopyridine indoles) | |
| CN106536480A (zh) | 吡咯烷‑2,5‑二酮衍生物、药物组合物及用作ido1抑制剂的方法 | |
| BR0010783A (pt) | Novos compostos, seu uso e preparação | |
| EP2590981B1 (en) | Novel homopiperazine derivatives as protein tyrosine kinase inhibitors and pharmaceutical use thereof | |
| RU96103653A (ru) | Бициклические тетрагидропиразолопиридины | |
| DK0665843T3 (da) | Substituerede quinuclidiner som substans P-antagonister | |
| NO832530L (no) | Analogifremgangsmaate for fremstilling av terapeutisk aktive tieno(3,2-c)pyridin-derivater | |
| BR0010366A (pt) | Composto, composição farmacêutica, método de preparar um composto, e, composto para uso em terapia | |
| WO1995019362A1 (en) | Dihydro pyrazolopyrroles | |
| BRPI0708016A2 (pt) | composto ou um sal, solvato ou n-óxido do mesmo, composição farmacêutica, uso de um composto ou um sal, solvato ou n-óxido do mesmo, e, método para o tratamento e/ou prevenção de distúrbios | |
| RU96111027A (ru) | Трициклические 5,6-дигидро-9h-пиразоло [3,4-c]-1,2,4-триазоло [4,3-a]пиридины | |
| BRPI0517412A (pt) | derivados de benzodiazepina substituìdos | |
| NO154089C (no) | Analogifremgangsmaate for fremstilling av terapeutisk aktive imidazolderivater. | |
| SE8307133D0 (sv) | Carboxamido-derivatives of 5h-1,3,4-thiadiazolo(3,2-a)pyrimidines and process for their preparation | |
| MXPA05012377A (es) | Derivados de imidazotiazoles e imidazoxazol como inhibidores de p38. | |
| ES2687450T3 (es) | Nuevo derivado de furanona | |
| CZ20021531A3 (cs) | Chinolinové a naftyridinové deriváty a karboxylové kyseliny | |
| KR910015580A (ko) | 신규 콜린에스테라제 억제제로서의 삼환-일환식 아민 | |
| KR890017252A (ko) | 티에노트리아졸로디아제핀 화합물 및 그의 약학적 용도 | |
| JP7335344B2 (ja) | Ａｌｋ４／５阻害剤としての縮合環ヘテロアリール化合物 | |
| KR910020018A (ko) | 피리도[3, 4-b] 피롤로[1, 2-e][1, 4, 5]옥사디아제핀 및 이의 관련 동족체 이의 제조방법 및 약제로서의 이의 용도 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant | ||
| FPAY | Annual fee payment |
Payment date: 20061229 Year of fee payment: 9 |
|
| LAPS | Lapse due to unpaid annual fee |